NCT00245505

The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease"

The Effect on Mucosal Healing With Pentasa Sachet 4g in Mild to Moderate Active Small Bowel Crohn´s Disease, Evaluated by Video Capsule Endoscopy After 6 and 12 Weeks Treatment. A Pilot Study

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Ferring Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to visualize the healing effect on mucosal lesions with Pentasa Sachet 4g in patients with mild to moderate active small bowel CD by video capsule endoscopy.

Detailed description

The purpose of this study is to visualize the healing effect on mucosal lesions with Pentasa Sachet 4g in patients with mild to moderate active small bowel CD by video capsule endoscopy

Conditions

• Crohn's Disease

Interventions

Type	Name	Description
DRUG	Mesalazine (Mesalamine)	Pentasa (mesalazine) sachets 2 g morning + 2 g evening during 12 weeks treatment

Timeline

• Start date: 2009-02-01
• Primary completion: 2009-06-01
• Completion: 2009-07-01
• First posted: 2005-10-28
• Last updated: 2012-03-12

Locations

1 site across 1 country: Sweden